Physician profile
June Mbae
NPI 1922531136
$469.97
in general payments reported to CMS, 2019-2025
10 companies · $50.16 in 2025
The $50.16 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $180 · 2024: $240 · 2025: $50.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.49 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.04 | 2023-2024 | Ofev |
| Intuitive Surgical, INC. | $100.08 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $58.31 | 2023-2024 | Fasenra |
| Glaxosmithkline, LLC. | $43.80 | 2023-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Merck Sharp & Dohme LLC | $32.87 | 2023 | Zerbaxa, Recarbrio |
| Insmed, INC. | $32.48 | 2024 | Arikayce |
| Ambu INC. | $26.98 | 2024 | |
| United Therapeutics Corporation | $20.86 | 2024 | Tyvaso |
| Philips North America LLC | $16.86 | 2024 | (8874) Incourage |
| Inogen, INC. | $14.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw June Mbae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.